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Loss of TET2 in hematopoietic cells
leads to DNA hypermethylation
of active enhancers and induction
of leukemogenesis
Kasper D. Rasmussen,1,2 Guangshuai Jia,1,2 Jens V. Johansen,1 Marianne T. Pedersen,1,2
Nicolas Rapin,1,3,4,5 FrederikO. Bagger,1,3,4,5 Bo T. Porse,1,3,4,5 Olivier A. Bernard,6 Jesper Christensen,1,2
and Kristian Helin1,2,3
1Biotech Research and Innovation Centre (BRIC), 2Centre for Epigenetics, University of Copenhagen, 2200 Copenhagen,
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DNAmethylation is tightly regulated throughoutmammalian development, and alteredDNAmethylation patterns
are a general hallmark of cancer. The methylcytosine dioxygenase TET2 is frequently mutated in hematological
disorders, including acute myeloid leukemia (AML), and has been suggested to protect CG dinucleotide (CpG) is-
lands and promoters from aberrant DNA methylation. In this study, we present a novel Tet2-dependent leukemia
mousemodel that closely recapitulates gene expression profiles and hallmarks of humanAML1-ETO-inducedAML.
Using thismodel, we show that the primary effect ofTet2 loss in preleukemic hematopoietic cells is progressive and
widespread DNA hypermethylation affecting up to 25% of active enhancer elements. In contrast, CpG island and
promoter methylation does not change in a Tet2-dependent manner but increases relative to population doublings.
We confirmed this specific enhancer hypermethylation phenotype in human AML patients with TET2mutations.
Analysis of immediate gene expression changes reveals rapid deregulation of a large number of genes implicated in
tumorigenesis, including many down-regulated tumor suppressor genes. Hence, we propose that TET2 prevents
leukemic transformation by protecting enhancers from aberrant DNA methylation and that it is the combined si-
lencing of several tumor suppressor genes in TET2mutated hematopoietic cells that contributes to increased stem
cell proliferation and leukemogenesis.
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Methylation of DNA at CG dinucleotides (CpGs) plays an
important function in the maintenance of cell identity as
well as the regulation of developmental processes (Mes-
serschmidt et al. 2014). A large number of studies have
shown that patterns of DNA methylation are perturbed
in human diseases such as imprinting disorders and can-
cer (Baylin and Jones 2011). In cancer, these studies have
almost exclusively focused on CpG island methylation,
and it has been shown that several tumor suppressor genes
are silenced by this mechanism (Baylin and Jones 2011).
Although it is well established that the CpG islands be-
comes increasingly methylated as a function of age (so-
called “epigenetic drift”), the mechanisms leading to the
changes in DNAmethylation patterns are not well under-
stood (for review, see Teschendorff et al. 2013; Issa 2014;
Schoofs et al. 2014). However, the recent discovery that
primary tumors carry mutations in genes involved in
the regulation of DNAmethylation, includingDNMT3A,
IDH1, IDH2, and TET2, suggests that somatic mutations
in specific genes might contribute to the altered DNA
methylation patterns in cancer (Shih et al. 2012).
TET2 is amember of the TET family of proteins (TET1–
3) that can convert 5-methylcytosine (5mC) to 5-hydroxy-
methylcytosine (5hmC) and promotes site-specific DNA
demethylation (Pastor et al. 2013). TET2 is the only gene
of the TET family that is mutated with high frequency
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in patients suffering from a wide variety of hematopoie-
tic diseases (for review, see Solary et al. 2014), including
malignancies such as myelodysplastic syndrome (MDS)
(Delhommeau et al. 2009; Langemeijer et al. 2009; Mes-
serschmidt et al. 2014), chronic myelomonocytic leuke-
mia (CMML) (Kosmider et al. 2009; Baylin and Jones
2011), acute myeloid leukemia (AML) (Baylin and Jones
2011; Weissmann et al. 2012), and B- and T-cell lympho-
mas (Quivoron et al. 2011; Asmar et al. 2013; Teschen-
dorff et al. 2013; Issa 2014; Schoofs et al. 2014). Genetic
inactivation of Tet2 in the mouse hematopoietic system
confers a competitive advantage to stem and progenitor
cells and disrupts terminal differentiation, resulting in a
CMML-like phenotype (Li et al. 2011; Moran-Crusio
et al. 2011; Quivoron et al. 2011; Shide et al. 2012; Shih
et al. 2012). Although this leads to increased susceptibility
to cellular transformation, the resulting hematopoietic
malignancies occur with low penetrance. Therefore, in
both human patients and mouse models, the kinetics of
disease development suggests that cooperating mutations
are necessary to achieve full malignant transformation. In
accordance, cooperation of Tet2 deficiency with KIT acti-
vation (Soucie et al. 2012; Pastor et al. 2013) and with in-
activation of the Notch pathway (Lobry et al. 2013; Solary
et al. 2014) was recently demonstrated. However, the
mechanistic role of Tet2 loss in this process remains
unknown.
Despite several reports, it is not clear how TET2muta-
tions affect DNAmethylation patterns in the genome and
contribute to hematological disorders. Initial analysis re-
vealed global hypomethylation in TET2 mutated versus
TET2 wild-type CMML patients (Ko et al. 2010). Subse-
quently, this observation was partly validated by an addi-
tional study that found the majority of differentially
methylated promoters (43 out of 56) in CMML patients
to be hypomethylated (Pérez et al. 2012). In contrast, an-
other group found increased methylation in 129 promot-
ers in AML patients with TET2 mutations (Figueroa
et al. 2010). Finally, Yamazaki et al. (2012) found that
CMML patients with TET2mutations had global increase
in DNA methylation, and since they were not able to
detect increased methylation at several loci investigated,
they speculated that the increase in DNA methylation
most likely occurred outside of CpG islands and gene
promoters. In support of this notion, two recent reports re-
vealed a potential role of Tet proteins in the maintenance
of DNA methylation on enhancer elements (Hon et al.
2014; Lu et al. 2014); however, the relevance of this obser-
vation for hematopoietic cells and tumorigenesis is not
clear at present. To investigate the role of Tet2 in the reg-
ulation of DNA methylation in hematopoietic cells and
how its loss can contribute to hematopoietic disorders,
we generated a mouse model for Tet2-deficient AML. Us-
ing thismodel in combinationwith in vitro studies on pre-
leukemic cells, we demonstrated that loss of Tet2 led to a
genome-wide increase in DNA methylation of active en-
hancers over time. Several of these enhancers regulate
the expression of tumor suppressor genes, and we propose
that the combined silencing of these contributes to in-
creased stem cell proliferation and tumorigenesis.
Results
Loss of Tet2 and AML1-ETO (AE) expression collaborate
to induce AML
To understand the role of TET2 in the development of leu-
kemia, we sought to develop a mouse model of human
AMLdependent on the loss ofTet2 activity. The combina-
tion of TET2mutations and the t(8:21)(q22:q22) transloca-
tion has been observed in both pediatric and adult de novo
AML patients (Supplemental Table S1). We therefore de-
cided to combine Tet2 deficiency with expression of AE,
the oncofusion protein emanating from the t(8;21) translo-
cation.We first investigated the effect of disruptingTet2 in
a serial replating assay using Kit-enriched hematopoietic
stem and progenitor cells (HSPCs) expressing AE or empty
vector (EV).Whereas bothTet2−/−;EVandTet2fl/fl;AE cells
showed a low basal colony formation capacity, the combi-
nation of Tet2 disruption and AE expression led to a dra-
matic and permanent increase in colony-forming unit
(CFU) numbers and colony sizes, indicating a strong syner-
gistic effect (Fig. 1A; Supplemental Fig. S1A).
Next, we investigated AML development in vivo using
mouse bone marrow transplantation assays. Lethally irra-
diated SJLmicewere transplanted with Tet2fl/fl or Tet2−/−
HSPCs transducedwith AE andmonitored for hematopoi-
etic abnormalities. The majority of mice (12 out of 13)
transplanted with Tet2−/−;AE HSPCs succumbed to leu-
kemia with a median latency of 6 mo, whereas mice re-
ceiving Tet2fl/fl;AE HSPCs (12 out of 12) remained
healthy over a 12-mo observation period. Of note, splenic
cells frommoribund leukemic mice gave rise to leukemia
with accelerated onset when transplanted into suble-
thally irradiated secondary recipient mice (Fig. 1B). Loss
of Tet2 also greatly accelerated the onset of disease
when combined with a truncated version of the AE fusion
protein (AML1-ETO9a) that is sufficient to induce leuke-
mia (Supplemental Fig. S1B; Yan et al. 2006).
The diseasedmice transplantedwithTet2−/−;AEHSPCs
suffered from leukocytosis and severe anemia, indicated
by increased numbers ofwhite blood cells (WBCs) and a re-
duction of red blood cells (RBCs) and hematocrit value in
theperipheral blood (Fig. 1C). In addition, themice showed
greatly increased spleen sizes (Fig. 1D) accompanied by
disruption of splenic architecture and infiltration of leuke-
mic blasts in the spleen, liver, and bone marrow (Supple-
mental Fig. S1C). Further analysis of peripheral blood
and bone marrow using flow cytometry revealed that the
GFP-positive leukemic blasts had lost expression of
CD45 (Fig. 1E), a hallmark of t(8:21) AML patients (Lo
et al. 2012), and displayed an immatureGMP-likemyeloid
immunophenotype (Supplemental Fig. S1D,E).
To investigate the validity of this model, we performed
gene expression analysis on sorted leukemic GMP
(L-GMP) cells from secondary recipient animals trans-
planted with splenocytes isolated from two independent
moribond mice (LeuA and LeuB) (Fig. 1B). Unsupervised
hierarchical clustering with human AML samples in the
MILE study (Haferlach et al. 2010) and TCGA study
(The Cancer Genome Atlas Research Network 2013) us-
ing the 10% most varying gene homologs revealed that,
Tet2 and enhancer methylation in AML
GENES & DEVELOPMENT 911
 Cold Spring Harbor Laboratory Press on May 16, 2019 - Published by genesdev.cshlp.orgDownloaded from 
whereas wild-type GMP cells from control mice clustered
with normal human GMP cells, murine Tet2−/−;AE L-
GMP cells clustered closely together with t(8:21) AML pa-
tients aswell as patients carryingTET2mutations (Fig. 1F;
Supplemental Fig. S1F). Hence, disruption of Tet2 collab-
orates with AE in vitro and in vivo to induce a lethal and
transplantable leukemia that recapitulates the hallmarks
of human t(8;21) and TET2mutated AML disease.
Deletion of Tet2 in preleukemic hematopoietic cells
expressing AE leads to accelerated in vitro cell
proliferation and gene expression changes associated
with human AML with TET2mutations
Development of leukemia in an in vivo mouse model is a
complex process often resulting in a heterogeneous pool of
leukemic cells with diverse differentiation states and self-
renewal capabilities. Thus, to investigate the primary reg-
ulatory effects of Tet2 disruption in hematopoietic cells,
we developed an in vitro-based cell culture system. We
crossed mice harboring the inducible Rosa26-CreERT2 al-
lele with Tet2fl/fl mice to obtain Tet2fl/fl;Rosa26+/CreERT2
(referred to as Tet2fl/fl: CreER) double-transgenic animals.
HSPCs isolated from mice of this genotype were trans-
duced with AE, grown for three rounds of serial replatings
in methylcellulose, and shifted to culture in liquid medi-
um supplemented with cytokines. This resulted in inde-
pendent cell cultures characterized by a population of in
vitro GMP (iGMP) cells (B220+, CD3e−, Gr1−, CD11b−,
and CD16/32+) that had gained self-renewal potential
but retained the capacity to differentiate to mature cells
of the granulocytic lineage (Gr1+CD11b+). Treatment
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Figure 1. Loss of Tet2 and AE expression
collaborate to induceAML. (A) Serial replat-
ing assay in methylcellulose-containing
medium of Tet2fl/fl or Tet2−/− Kit-enriched
HSPCstransducedwitheitherEV-orAE-ex-
pressing retrovirus.Bars representmeanval-
ue (n = 3), and error bars indicate SD. (∗) P <
0.025 (two-way ANOVA); (n.s) not signifi-
cant. (B) Kaplan-Meier plot showing overall
recipient mouse survival upon primary (1°)
or secondary (2°) transplantation. (Left) Le-
thally irradiated (900 Rad) recipient SJL
mice transplanted with Tet2fl/fl (n = 13) or
Tet2−/− (n = 12) Kit-enriched HSPCs trans-
duced with AE-expressing retrovirus.
(Right) Sublethally irradiated (650 Rad) re-
cipient mice (n = 5) transplanted with 1 ×
106 splenocytes isolated frommoribundleu-
kemic Tet2−/−;AE mice (LeuA). (∗∗∗∗) P-val-
ue < 0.0001 (Wilcoxon test). LeuA and
LeuB mark the origins of two Tet2−/−;AE
leukemias from independent mice used for
secondary transplantation experiments
and gene expression analysis. (C ) Peripheral
blood parameters of wild-type (WT)mice (n
= 4) or moribund mice transplanted with
Tet2−/−;AE HSPCs (n = 7). (∗) P < 0.01 (Stu-
dent’s t-test). (D) Splenomegaly observed in
moribund mice transplanted with Tet2−/−;
AE HSPCs, as indicated by spleen versus
bodyweight ratio (n = 4) (left panel) or visual
inspection (n = 3) (right panel). (∗∗∗) P <
0.0001 (Student’s t-test). (E) Representative
FACS analysis plots of peripheral blood
from recipient mice showing the CD45.2-
positive Tet2fl/fl;AE (top panel) or Tet2−/−;
AE (bottom panel) cells as well as the
CD45.1-positive helper cells (wild type).
Earlysignsofdisease includetheappearance
of CD45-negative and GFP-positive leuke-
mic blasts in circulation. (F ) Unsupervised
hierarchical clustering of mouse wild-type GMPs and leukemic GMPs (L-GMPs; LeuA and LeuB) together with human AML samples
fromtheMILEstudy (Haferlachetal. 2010) (left) andtheCancerGenomeAtlas (TCGA)study (TheCancerGenomeAtlasResearchNetwork
2013) (right). Forclarity, eachkaryotypicsubgroupintheMILEstudy is limitedto10patientsshowingthehighest intrasamplecorrelation. In
addition,TCGApatientswithco-occurringmutations inmultiplegenes involved inDNAmethylation (TET1,DNMT3A,DNMT3B, IDH1,
and IDH2) were excluded, and only patients withTET2mutations and/or t(8;21) translocations as well as an APL control group are shown.
Samples with TET2mutation are reported with red stars. See Supplemental Figure S1 for additional clustering analysis.
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with 4-hydroxytamoxifen (4-OHT) for two passages re-
sulted in complete loss of full-length Tet2 mRNA with
no effect on the level of AE expression (Supplemental
Fig. S2A–D). In addition, the cells showed a twofold to
fourfold reduction in endogenous 5-hmC levels, indicat-
ing that the catalytic activity of Tet2 was efficiently
disrupted (Fig. 2A). Due to the high efficiency of recombi-
nation, EtOH control and 4-OHT-treated cultures derived
from Tet2fl/fl;AE;CreER animals are hereafter referred
to as Tet2fl/fl;AE and Tet2−/−;AE, respectively. In con-
trast to previous observations in Tet2 knockout animals,
morphological and flow cytometry analysis revealed that
granulocytic differentiation was unperturbed in Tet2−/−;
AE cultures (Fig. 2B; Supplemental Fig. S2E,G). However,
similar to what was observed in semisolid medium,
Tet2−/−;AE cells showed a pronounced and lasting accel-
eration of cell proliferation compared with Tet2fl/fl;AE
cells (average doubling time ∼20 h vs. ∼27 h) (Fig. 2C).
In part, this was due to a cell type-specific decrease of
apoptotic rate in iGMP cells in the Tet2−/−;AE cul-
tures, indicating that loss of Tet2 confers a distinct sur-
vival advantage to this cell population (Supplemental
Fig. S2H).
To gain insight into the onset and progression of effects
associated with Tet2 disruption in iGMP cells, we per-
formed gene expression analysis at both early (passage 2)
and late (passage 10) stages. Tet2 disruption resulted in
significant deregulation of 225 genes, of which 47 were
changed more than twofold (Fig. 2D; Supplemental Table
S2). Among these, many genes with known roles in stem
cell function, leukemogenesis, and cancer were identified.
These include several down-regulated putative tumor
suppressor genes (e.g., Mtss1, Las2, Lxn, Ctdspl, Grap2,
etc.) and up-regulated putative oncogenes (e.g., Aff3,
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Figure 2. Disruption of Tet2 in preleuke-
mic AE cell cultures leads to gene expres-
sion changes similar to those found in
human AML with TET2 mutations. (A)
Overview of experimental setup (top) and
quantification of global 5hmC levels by dot
blotting (bottom). Genomic DNA isolated
from biological duplicate cultures (Rep1
andRep2) ofTet2fl/fl;AE;CreERcells treated
with EtOH (control) or 4-OHT (induction of
Tet2 disruption)were assayed. To showspe-
cificity, genomic DNA from wild-type or
DNMT triple-knockout embryonic stem
(ES) cells (Tsumura et al. 2006) as well as
synthetic oligonucleotides were included.
(B) Representative FACS plots showing
populations of immature iGMP cells
(GFP+CD3e−B220−Gr1−Mac1−CD16/32+)
as well asmature Gr1+Mac1+myeloid cells.
Both Tet2fl/fl;AE (top panel) and Tet2−/−;AE
(bottom panel) cultures show sign of granu-
locyticdifferentiation. (C )Accelerated invi-
tro proliferation of AE cells upon disruption
ofTet2.Cumulativecellnumbersoraverage
doubling time (inset) of Tet2fl/fl;AE and
Tet2−/−;AE cell cultures (n = 3). Cells were
counted and plated at equal cell density
every second day for a period of 20 d. Sym-
bols show mean cell number, and error
bars indicate SD. (∗∗∗∗)P < 0.0001 (nonlinear
regression). (D) Heat map of the top dif-
ferentially expressed genes (false dis-
covery rate [FDR] < 0.05, fold change >2) in
sorted iGMP cells isolated from triplicate
Tet2fl/fl;AE and Tet2−/−;AE cultures grown
for two and 10 passages, respectively. In-
dividual expression values were normal-
ized, and the z-scores for each gene are
presented. See Supplemental Table S2 for a
full list of differentially expressed genes. (E) Tet2−/−;AE cells cluster closely with TET2mutated AML patients, indicating that gene ex-
pression changes observed in iGMP cells upon Tet2 deletion are relevant to gene signatures of TET2mutated AML patients. Differential
gene expression-based hierarchical clustering of preleukemic Tet2fl/fl;AE and Tet2−/−;AE cells together with patients from TCGA (The
Cancer Genome Atlas Research Network 2013) are shown. For clarity, patients with co-occurring mutations in multiple genes involved
in DNA methylation (TET1, DNMT3A, DNMT3B, IDH1, and IDH2) were excluded, and only patients with TET2 mutations and/or
t(8;21) translocations as well as an APL control group are shown. See also Supplemental Figure S2 for additional clustering analysis.
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Pim2, Nepn, Notch3, Igf1r, etc.) as well as many genes of
unknown significance. The deregulated expression of
many of these genes was validated by quantitative RT–
PCR (qRT–PCR) on independently derived cultures (Sup-
plemental Fig. S2I). Of note, these genes were not affected
in nonleukemic GMP cells with Tet2 disruption, imply-
ing a context-specific role of Tet2 in gene regulation (Sup-
plemental Fig. S2J).
Finally, we tested whether the gene expression changes
observed in the iGMP cells were similar to those occur-
ring in human AML patients. Remarkably, clustering
analyses based on differentially expressed genes (Supple-
mental Table S2) showed that iGMP cells, upon disrup-
tion of Tet2, cluster closely with AML patient samples
carrying TET2 mutations as compared with Tet2fl/fl;AE
iGMP cells, t(8;21) patients, and an APL control group
(Fig. 2E). Furthermore, clustering based on sample correla-
tion revealed that two out of three passage 10 Tet2−/−;AE
samples clustered specifically together with a patient
carrying a t(8:21)/TET2 double mutation, corroborating
the relevance of prolonged cell passaging and Tet2 dele-
tion to humanAMLwith these aberrations (Supplemental
Fig. S2K). Thus, the preleukemic Tet2fl/fl;AE and Tet2−/−;
AE in vitro-cultured cells represent a physiologically rele-
vant and tractable cellular system to study the primary
role of Tet2 disruption on DNAmethylation and gene ex-
pression in hematopoietic cells.
5hmC is specifically lost at enhancer elements
The lack of Tet2-specific antibodies for chromatin immu-
noprecipitation (ChIP) prompted us to investigate the spe-
cific distribution of 5hmC as a surrogate marker of Tet2
occupancy and catalytic activity. Therefore, we per-
formed 5hmC DNA immunoprecipitation (DIP) sequenc-
ing (5hmC-DIP-seq) on biological duplicate Tet2fl/fl;AE
and Tet2−/−;AE cultures. Despite globally reduced
5hmC levels, initial analysis of summarized read densities
across different genomic elements previously mapped in
MEL cells revealed only a modest decrease of 5hmC at
DNaseI sites, with little or no change at CpG islands, pro-
moters, gene bodies, and Ctcf sites (Supplemental Fig.
S3A). Thus, to discern the effect on DNaseI sites, we
mapped enhancers and promoters based on duplicate
ChIP-seq (ChIP combined with deep sequencing) profiles
of H3K4me1, H3K4me3, and H3K27ac from Tet2fl/fl;AE
and Tet2−/−;AE cells. Heat map visualization of normal-
ized 5hmC read densities in wild-type cells showed that
out of the 8739 enhancers mapped, about one-third was
enriched in 5hmC. Upon Tet2 disruption, the same set
of enhancers showed a marked depletion of 5hmC, which
was also evident in summarized reads over all enhancers
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Figure 3. 5hmC is specifically lost at en-
hancers. (A) Heatmap showing an overview
of 5hmC-DIP-seq read density on all 8739
enhancers in duplicate cultures of Tet2fl/fl;
AE and Tet2−/−;AE cells. The top panel
shows 2999 enhancers enriched in 5hmC
in wild-type and depleted of 5hmC upon
Tet2 knockout (mean log2 fold change
>0.5), whereas the bottom panel shows
the remaining enhancers. Each row repre-
sents a 20-kb window centered on an en-
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kb downstream. (B) Summarized 5hmC-
DIP-seq read densities across all 8739 en-
hancers in duplicate cultures of Tet2fl/fl;
AE and Tet2−/−;AE cells. See Supplemental
Figure S3 for other genomic elements. (C )
Representative UCSC tracks showing spe-
cific loss of a 5hmC peak in an enhancer
in the Zfp128 locus. The top tracks show
5hmC-DIP-seq enrichment data from bio-
logical duplicate cultures of Tet2fl/fl;AE
and Tet2−/−;AE, respectively. The bottom
tracks represent histone ChIP-seq experi-
ments performed on Tet2fl/fl;AE and
Tet2−/−;AE cells showing enrichment of
H3K27ac, H3K4me1, and H3K4me3, re-
spectively. (D) 5hmC-DIP followed by
qPCR in independent biological triplicate
samples. Primers directed against the
Zfp128 enhancer as well as an unchanging
downstreampeak are shown. Bars represent
mean enrichment over input, and error bars indicate SD. (∗) P-value < 0.05 (Student’s t-test). See also Supplemental Figure S3 for validation
of additional loci.
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S3B). Finally, depletion of 5hmC was also confirmed
on several enhancers using 5hmC-DIP-qPCR on indepen-
dently derived cell cultures (Fig. 3C,D; Supplemental Fig.
S3C). Together, these results demonstrate that 5hmC is
specifically lost from enhancer elements upon Tet2 dis-
ruption in hematopoietic cells.
Loss of TET2 leads to preferential hypermethylation
of enhancer elements
Hydroxylation of 5mC has been implicated in both active
and passive demethylation processes (for review, see Pas-
tor et al. 2013). We therefore hypothesized that the specif-
ic loss of 5hmC on enhancer elements would make these
prone to increasedDNAmethylation. To test this, we per-
formed enhanced reduced representation bisulfite se-
quencing (eRRBS) Akalin et al. 2012) on early (passage 2)
and late (passage 10) stage Tet2fl/fl;AE and Tet2−/−;AE cul-
tures. Approximately 70% of reads could be aligned to the
genome, yielding information about ∼2.3 million individ-
ual CpGs, each covered by >10 reads in all samples (see
Supplemental Fig. S4A for detailed information of genome
coverage).
We then focused on analyzing the differences in meth-
ylation across the four conditions. We reasoned that the
methylation state of a given locus could be influenced
by the absence of Tet2 catalytic activity (Tet2-dependent
effect) but also by prolonged passaging of cells in culture
(passage-dependent and age-related changes known as epi-
genetic drift). Interestingly, analysis of average DNA
methylation (Supplemental Fig. S4B) or DNA methyla-
tion of individual CpGs within enhancer elements (Fig.
4A,B) revealed a striking and progressive Tet2-dependent
hypermethylation at both early and late passage cells.
However, when comparing all genomic elements, we not-
ed that a large fraction of the CpGs covered in the analysis
did not change in any condition. To exclude these and ob-
tain a comparable measure of methylation change, we
defined variable CpGs within each genomic element
[Q-value < 0.05, abs(diff) > 20%] and calculated the mean
difference in methylation. In this measure, two-way
changes in methylation state (equal hypermethylation
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Figure 4. eRRBS reveals preferential DNA
hypermethylation in enhancer elements.
(A) DNA methylation scatter plot showing
methylation levels of individual CpG sites
in enhancer elements. Methylation levels
are shown for Tet2fl/fl;AE (Y-axis) and
Tet2−/−;AE (X-axis) cultures at passage 2
(left panel) or passage 10 (right panel) after
Tet2 disruption. CpG sites that are chang-
ing significantly [Q-value < 0.05; abs(diff)
> 20%] are marked in red. (B) Cumulative
distribution plot showing the methylation
levels on all covered CpGs in enhancer ele-
ments. (Inset) Tet2-deficient cells have
overall increased level of DNAmethylation
on enhancers upon cell passaging (p10 vs.
p2 Tet2−/−;AE cells), indicating progressive
hypermethylation. (C ) Bar chart showing
passage-dependent effects onDNAmethyl-
ation in Tet2fl/fl;AE cells. Bars represent
mean change of DNA methylation in the
indicated genomic elements between pas-
sage 10 and passage 2. (D) Bar chart showing
Tet2-dependent effects on DNA methyla-
tion at passage 2 (left panel) and passage
10 (right panel). Bars represent mean chan-
ge of DNAmethylation in the indicated ge-
nomic elements between Tet2−/−;AE
(knockout) and Tet2fl/fl;AE (wild type). In
both C and D, only CpG sites that showed
significantly different DNA methylation
levels [Q-value < 0.05; abs(diff) > 20%]
were considered. The effect size of methyl-
ation change at each element was measured with Cohen’s d. (∗) Cohen’s d between 0.5 and 1.0; (∗∗) Cohen’s d > 1.0. See Supplemental
Figure S4 for details. (E) Serial replating assay of Tet2fl/fl or Tet2−/− Kit-enriched HSPCs transduced with MLL-AF9-expressing retrovirus.
The cells were replated in methylcellulose-containing medium (M3534) every 5 d for a total of four replatings. Bars represent mean num-
bers of CFUs (n = 3), and error bars indicate SD. (F ) Cumulative growth curve of Tet2fl/fl;MLL-AF9 or Tet2−/−;MLL-AF9 cultures (n = 3)
grown for 10 passages. Cellswere counted and plated at equal cell density every second day for a total of 20 d. (ns.) not significant (nonlinear
regression). (G) Bar chart showing mean change of DNA methylation in the indicated genomic elements between Tet2−/−;MLL-AF9
(knockout) and Tet2fl/fl;MLL-AF9 (wild-type) cells 20 passages after Tet2 disruption. Mean changes of DNAmethylation and genomic el-
ements are presented in C and D. (∗) Cohen’s d between 0.5 and 1.0.
Tet2 and enhancer methylation in AML
GENES & DEVELOPMENT 915
 Cold Spring Harbor Laboratory Press on May 16, 2019 - Published by genesdev.cshlp.orgDownloaded from 
and hypomethylation) would result in a value close to 0,
whereas a strong one-way effect (e.g., predominant hyper-
methylation) would result in deviation from this baseline.
First, we analyzed Tet2fl/fl;AE cells at early and late pas-
sage numbers to evaluate passage-dependent (and Tet2-
independent) drift in DNA methylation levels. Interest-
ingly, and in agreement with previous reports studying
primary cell culture systems (Meissner et al. 2008; Landan
et al. 2012) as well as aged mice and MDS patients (Mae-
gawa et al. 2014), we could observe a strong passage-de-
pendent hypermethylation of CpG sites within CpG
islands and promoters (Fig. 4C; Supplemental Fig. S4B).
However, strikingly, when we analyzed the Tet2-depen-
dent effect in Tet2−/−;AE versus Tet2fl/fl;AE cells at pas-
sages 2 and 10 following Tet2 disruption, we observed a
significant hypermethylation of CpG sites in enhancer el-
ements at both early and late passage cells, with little or
no effect onDNAmethylation in other genomic elements
(Fig. 4D). It is noteworthy that Tet2 disruption had no
detectable effect on DNA methylation of either CpG is-
lands or promoters.
Since the increased DNA methylation of enhancer ele-
ments could be a result of a selection process dependent
on the AE transgene and not only a result of Tet2 deletion,
we decided to test the effect of Tet2 disruption in the con-
text of the unrelated MLL-AF9 human oncofusion pro-
tein. Importantly, loss of Tet2 in HSPCs immortalized
with the MLL-AF9 oncogene does not give any selective
advantage as measured by colony formation in semisolid
medium (Fig. 4E) or cell growth during prolonged passag-
ing in liquid culture (Fig. 4F). Consistentwith the observa-
tion using AE-dependent preleukemic cells, loss of Tet2
in immortalized MLL-AF9 cells grown for 20 passages
led to selective hypermethylation of putative enhancer
elements (Fig. 4G). In summary, these results show that
Tet2 disruption leads to preferential DNA hypermethy-
lation of enhancer elements during hematopoietic
transformation.
Increased DNA methylation on enhancers correlates
with loss of enhancer activity and lower expression
of nearby genes
Using independent data sets of 5hmC and DNAmethyla-
tion patterns, we showed that Tet2 disruption predomi-
nantly affects the epigenetic state of enhancers. Hence,
we asked whether the overlap of these data sets could be
used to find direct and high-confidence targets of Tet2.
To do so, we defined continuous regions within enhancers
(at least three CpGswithin 1 kb, covered by >10 reads) and
calculated themeanDNAmethylation difference to iden-
tify differentially methylated regions (DMRs). This yield-
ed 2017 enhancer regions in passage 10 cells, of which
22.7% was hypermethylated, and 1.1% was hypomethy-
lated [abs(mean difference) >10%]. As anticipated, a signif-
icant proportion of these hypermethylated enhancer
DMRs were also associated with loss of 5hmC (Fig. 5A;
Supplemental Fig. S5A), and we could successfully vali-
date the 5hmC and 5mC changes using independently de-
rived triplicate Tet2fl/fl;AE and Tet2−/−;AE cultures (Fig.
5B; Supplemental Fig. S3C). To assess the effect of DNA
methylation on enhancers, we defined the local (enhancer
DMR+ 250-base-pair [bp] flanking region) differential
H3K27ac enrichment as a surrogate marker of enhancer
activity as well as the normalized expression of genes
within 100 kb of each enhancer DMR in Tet2fl/fl;AE and
Tet2−/−;AE cells. Interestingly, increased DNA methyla-
tion correlates with loss of H3K27ac, suggesting that en-
hancers lose activity upon DNA hypermethylation (Fig.
5C; Supplemental Fig. S5C). Conversely, enhancers that
are lost upon Tet2 disruption (mapped in wild type but
not in knockout) also show the greatest increase in
DNA methylation (Supplemental Fig. S5D). Accordingly,
increased DNA methylation also correlates to some de-
gree with lower gene expression of nearby genes, albeit
only for enhancer DMRs with >30% increase in methyla-
tion (Fig. 5D). Attempts to correlate loss of 5hmC to differ-
ential H3K27ac and gene expression were unsuccessful,
suggesting that loss of 5hmC is not sufficient to yield a
detectable effect (Supplemental Fig. S5C).
To better understand the determining factors of hyper-
methylation and gene expression changes, we searched
for known transcription factor-binding motifs within
hypermethylated enhancer DMRs (Supplemental Fig.
S5D). Interestingly, both a known PU.1 motif (E-value
2.3 × 10−004), a key hematopoietic transcription factor,
and a Runx1 motif (E-value 2.3 × 10−002) were enriched
in the enhancer DMRs, suggesting that the hypermethy-
lated enhancers are important for normal hematopoiesis
and that AE (through its Runt domain) is affecting at least
part of the genes deregulated upon Tet2 knockout. In sup-
port of this, 52 of the 190 orthologous genes deregulated in
the preleukemic cells have previously been found to be
bound by AE in t(8;21) patients (Fig. 5E; Supplemental
Fig. S5E; Supplemental Table S1). Thus, these data suggest
that AE and TET2 are simultaneously affecting a subset of
enhancers as well as genes.
Disruption of Tet2 leads to DNA hypermethylation
of enhancers in GMP cells, embryonic stem (ES) cells,
and murine and human AML cells
To extend the findings in the in vitro grown preleukemic
cells to primary murine AML cells, we examined enhanc-
er methylation patterns in FACS-sorted GMP and L-GMP
cells (Fig. 6A). Quantitative bisulfite pyrosequencing of
three enhancers identified in the preleukemic in vitro sys-
tem confirmed a strong and specific Tet2-dependent en-
hancer hypermethylation in in vivo isolated GMP cells
(Fig. 6B). Specifically, we detected a reproducible increase
in methylation at enhancers upon disruption of Tet2
alone, whereas leukemic transformation with AE exacer-
bated this effect (∼15% vs. ∼43% mean increase). As ob-
served previously in the in vitro-grown cells (Fig. 4D),
we also detected a slight hypomethylation in GMP cells
with AE alone (∼12% mean decrease). Hence, these re-
sults suggest that the function of Tet2 is linked to enhanc-
er methylation both during normal hematopoiesis and in
malignant cells. Furthermore, we found that Tet2 knock-
out mouse ES cells also show a pronounced and specific
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enhancer hypermethylation, extending the role of Tet2 in
enhancer methylation to nonhematopoietic and nonma-
lignant cells (Supplemental Fig. S6).
Finally, to explorewhether enhancer hypermethylation
could be observed in humanAMLpatientswithTET2mu-
tations, we took advantage of a publicly available data set
(The Cancer Genome Atlas Research Network 2013) in
which 194 de novo AML patients were analyzed using
the Illumina Infinium 450k methylation array. Patients
were filtered based on the mutational status of genes in-
volved in regulation of DNA methylation, and the most
variable probes between an AML patient control group
having wild-type TET2 (n = 103) and patient groups with
either a TET2 mutation (n = 9), a t(8;21) translocation (n
= 6), or aDNMT3Amutation (n = 29) were extracted. Con-
sistent with previous studies, patients with TET2 muta-
tions showed an overall hypermethylation phenotype,
with 96.6% of significantly changing CpG sites showing
an increase in methylation (Fig. 6C). In contrast, patients
expressing mutant DNMT3A showed pronounced hypo-
methylation, and patients with t(8:21) translocation had
both hypermethylated and hypomethylated CpG sites
(Fig. 6C). Although the Infinium array is biased to assay
the methylation state of promoters and CpG islands, de-
tailed annotation revealed 8328 probes interrogating
CpGs within predicted human enhancers. Remarkably,
analysis of various genomic elements revealed a pro-
nounced enrichment of hypermethylated CpG sites in en-
hancers in TET2mutated patients (approximately fivefold
over background) (Fig. 6D). Conversely, this was not ob-
served in either hypermethylated CpG sites in t(8:21)
patients or hypomethylated CpG sites in t(8;21) patients
and patients with mutant DNMT3A (Fig. 6D,E). Finally,
we observed a depletion of hypermethylated sites at
CpG islands in TET2 mutated patients, suggesting, in
agreement with the in vitro system, that disruption of
TET2 does not result in CpG island hypermethylation.
Taken together, this analysis shows that disruption of
TET2 leads to specific hypermethylation of enhancer
elements in human AML cells, and this increase in hyper-
methylation appears to be independent of the other trans-
forming genetic events leading to leukemia.
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Figure 5. Loss of 5hmC and gain of meth-
ylation lead to decreased H3K27ac and
expression of neighboring genes. (A) Over-
view of 2107 regions in enhancers covered
by eRRBS. The percentage of enhancer
DMRs with an average DNA methylation
increase (blue; mean difference >10%) or
decrease (black; mean difference <−10%)
are shown (left pie chart) as well as the frac-
tion of hypermethylated enhancer DMRs
associated with loss of 5hmC (log2 fold
depletion >0.5) upon Tet2 knockout (right
pie chart). See Supplemental Table S3 for
full list of enhancer regions. (B) Quantita-
tive bisulfite pyrosequencing validation of
DNA methylation changes at four enhanc-
er DMRs (Mtss1, Fam105a, Tmem123,
and Las2 locus) associated with loss of
5hmC and gain of DNA methylation in
Tet2−/−;AE cells. Bar graphs showmethyla-
tion levels of each individual CpG within
the locus in cells grown for two or 10 pas-
sages following Tet2 disruption. Bars repre-
sent mean methylation (n = 3), and error
bars indicate SEM. (∗) P-value < 0.05; (∗∗) P-
value < 0.01; (∗∗∗∗) P-value > 0.0001 (two-
way ANOVA). (C ) Increase in DNA meth-
ylation levels at enhancer DMRs correlates
with loss of H3K27ac, a surrogatemarker of
enhancer activity. Violin plots show the
mean and lower and upper quartiles of the
log2 transformed differential H3K27ac read density (knockout/wild type) for enhancer DMR+ 250-bp flanking sequence. The 2107 en-
hancer DMRs have been divided into groups with <10% increase, 10%–30% increase, or >30% increase in DNA methylation levels
upon Tet2 knockout. (∗) P-value < 0.05; (∗∗∗∗) P-value < 0.0001 (unpaired Student’s t-test). (D) Increase in DNA methylation levels at en-
hancer DMRs correlates with decreased expression of genes within 100 kb. Violin plots show the mean and lower and upper quartiles
of average z-scores (knockout/wild type) of genes within 100 kb of enhancer DMRs. Subgroups and significance levels are presented as
in C. (E) Convergent gene regulation of AE and Tet2. Venn diagrams showing overlaps and corresponding P-values (Fisher’s test, Yates-
corrected) of genes deregulated in Tet2−/−;AE cells and genes bound by AE in AML patients (as described inMartens et al. 2012; Ptasinska
et al. 2012). (Right panel) Heatmap representing gene expression changes for genes differentially regulated byTet2 knockout and bound by
AE in both studies.
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Discussion
By generating and using a mouse model of human AE-in-
duced AML,we showed that loss of Tet2 in hematopoietic
cells led to a specific and progressive enhancer hyper-
methylation phenotype associated with altered gene ex-
pression, increased rate of cell accumulation, and
development of leukemia. In contrast, CpG islands and
gene promoters were not affected by Tet2 disruption but
experienced a slow increase of DNA methylation related
to the number of cell doublings; i.e., age-related epigenetic
drift. Hence, data from this and another study (Maegawa
et al. 2014) suggest that normal hematopoietic stem cells
will be subject to a slowaccumulation ofCpG islandDNA
methylation and that an acquired TET2 mutation will
lead to a relatively rapid increase in enhancer DNAmeth-
ylation conferring proliferation and survival advantage. In
turn, this combined effect on theDNAmethylome is like-
ly to directly or indirectly make the cell vulnerable to
additional oncogenic hits and full-blown leukemic trans-
formation (Fig. 7).
We and others have shown that Tet1 is preferentially lo-
calized to CpG islands and CpG-rich promoters through
binding of its CXXC domain to unmethylated CpGs (Wil-
liams et al. 2011; Wu and Zhang 2011). In contrast, the
lack of reliable antibodies for reproducible ChIP of Tet2
has made it difficult to establish a similar direct chroma-
tin interaction map. However, several studies examining
the genome-wide localization of 5hmC in ES cells have
suggested that Tet proteins can exert their activity on re-
gions outside CpG islands. In fact, using a range of differ-
ent techniques for 5hmC enrichment and sequencing, it
was shown that 5hmC is specifically enriched at lowly
methylated regions associated with enhancer elements
and CTCF insulators (Pastor et al. 2011; Stadler et al.
2011; Stroud et al. 2011; Williams et al. 2011; Yu et al.
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Figure 6. Disruption of Tet2 leads to
DNA hypermethylation of enhancers in
murine and human AML cells. (A) Over-
view of the strategy for in vivo isolation
of cells. GMP cells were sorted from the
bone marrow of recipient mice 1 mo after
transplantation of either wild-type or
Tet2−/− bone marrow, AE-transduced cKit
cells, or splenic cells from moribond
Tet2−/−;AE leukemic mice (LeuA and
LeuB) (see Fig. 1B). (B) DNA methylation
levels assayed by quantitative bisulfite
pyrosequencing at three enhancers
(Mtss1, Tmem123, and Pde2a locus) in
FACS-sorted wild-type (n = 4), Tet2−/− (n
= 4), AE-transduced (n = 4), or leukemic
Tet2−/−;AE (n = 8) GMP cells. Bars repre-
sent mean locus DNAmethylation, and er-
ror bars show SD. (∗) P-value < 0.05; (∗∗) P-
value < 0.01; (∗∗∗) P-value < 0.001; (∗∗∗∗) P-
value < 0.0001 (unpaired Student’s t-test).
(C ) Distribution of DNA methylation
changes of significantly changing CpGs
(P-value < 0.05 [Wilcoxon two-sample test,
abs(diff) > 20%] in AML patients with
TET2 mutations (left panel), t(8;21) trans-
location (middle panel), and DNMT3A
mutations (right panel). The percentages
of hypermethylated CpG sites versus all
significantly changing sites are indicated
on the plots. (D) Bar chart showing the dis-
tribution of the hypermethylated CpG
sites in AML patients with TET2mutation
or t(8:21) translocation across various ge-
nomic elements. The number of hyperme-
thylated CpG sites observed in each
element was normalized to the number ex-
pected by random distribution. The P-val-
ue for enhancer CpGs in TET2 mutated
patients is shown (Fisher’s exact test, Yates
correction). (DNMT3A mutated patients)
Not sufficient hypermethylated sites for
analysis. (E) As in C, but for probes hypomethylated in AML patients with DNMT3Amutations or t(8:21) translocation. (TET2mutated
patients) Not sufficient hypomethylated sites for analysis.
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2012; Hon et al. 2014). Here, using primary hematopoietic
cells, we report widespread 5hmC depletion on enhancers
upon Tet2 disruption, thus supporting a direct function-
al role of Tet2 on these elements. This was further
confirmed by eRRBS analysis that found 467 out of 2107
covered regions in enhancers to be hypermethylated, sug-
gesting that ∼25% of all enhancers in hematopoietic cells
become hypermethylated upon Tet2 disruption. Interest-
ingly, during the performance of this study, two studies
investigating the effect of knocking out Tet proteins in
mouse ES cells were published that found a similar pro-
portion of enhancers to be hypermethylated (Hon et al.
2014; Lu et al. 2014). Thus, considering that increased
methylation of enhancers has now been shown in both
malignant (AE and MLL-AF9 transformed) and nonmalig-
nant cell types (in vivo GMP and ES cells), it is likely that
TET2 has a general role in regulatingDNAmethylation of
enhancers in all cell types.
Along with promoters, associated enhancer elements
are important determinants of context-dependent tran-
scriptional output of genes (Plank and Dean 2014). Inter-
estingly, several recent studies suggest that DNA
methylation correlates negatively with enhancer activity
and gene transcription, possibly by interfering with tran-
scription factor binding (Stadler et al. 2011; Wiench
et al. 2011; Thurman et al. 2012). In addition, Aran et al.
(2013) examined both promoter and enhancer methyla-
tion with respect to gene expression and found that meth-
ylation of enhancers was a significantly better predictor of
gene expression. Using our data sets of enhancer DNA
methylation, 5hmC enrichment, and H3K27ac abun-
dance (surrogate marker of enhancer activity) as well as
expression of adjacent genes, we could show that enhanc-
er hypermethylation correlates negatively with levels of
the H3K27ac histone mark (Fig. 5C; Supplemental Fig.
S5C). Thus, our data suggest that increased DNAmethyl-
ation levels on enhancers decrease their activity by chang-
ing the chromatin environment and cause the down-
regulation of gene expression of nearby genes. It should
be noted that it was not possible to find a statistically sig-
nificant correlation between expression of the nearest
gene and changes in either enhancer DNA methylation
or 5hmC abundance (an effect likely masked due to com-
binatorial and redundant enhancer usage of individual
genes as well as subtle gene expression changes) (Supple-
mental Fig. S5C; Kasowski et al. 2013). However, when
considering all genes within 100 kb of the enhancer, in-
creased enhancer DNAmethylation correlated negatively
with gene expression, albeit only for enhancers with the
strongest gain of methylation (Fig. 5D).
Given these findings, it is tempting to speculate that in-
crease of DNAmethylation at one or a few enhancers can
be directly linked to deregulation of specific genes that in
turn results in oncogenic transformation. In our study, we
identified numerous such loci, including down-regulated
putative tumor suppressor genes (e.g., Mtss1, Las2, Lxn,
Ctdspl, Grap2, etc.) and up-regulated putative oncogenes
(e.g.,Aff3, Pim2,Nepn,Notch3, Igf1r, etc.) that constitute
interesting candidates for functional testing in future
studies. However, as previously mentioned, our results
also suggest that mutations of TET2 lead to genome-
wide enhancer hypermethylation affecting thousands
(up to 25%) of active enhancers. Hence, it is likely that
leukemogenesis inTET2mutated cells is not due to dereg-
ulation of a single gene (or a few) but rather proceeds
through a complex interplay between DNA methylation
of multiple enhancers and a subtle destabilization of ge-
netic networks. In addition, it should also be noted that
only limited evidence suggests a direct instructive role
of DNA methylation on CpG-poor regulatory regions
such as enhancers (for review, see Schübeler 2015). Ac-
cordingly, it is rather the global and simultaneous pertur-
bation of DNA methylation on numerous loci, although
modest when observing only a single locus, that might ac-
count for the strong phenotype observed upon disruption
of TET2 function. Finally, we believe that such a global
mechanism could explain why TET2 mutations are not
limited to a specific subtype of hematopoietic disease
but co-occur frequentlywith a broad range of genetic aber-
rations in various hematopoietic disorders (Solary et al.
2014).
For decades, analysis of DNAmethylation in cancer pa-
tients has been focused on promoter-proximal CpG is-
lands and gene bodies. Instead, our results now suggest
that analysis of TET2 mutated patients should be aimed
at deciphering the effect on DNA methylation levels at
enhancer elements. It is interesting to note that the fre-
quency of somatic TET2mutations is strongly age-related
and that these have been described in otherwise healthy
elderly individuals with clonal hematopoiesis (Busque
et al. 2012). In addition, several studies have pointed to
TET2 mutations as an early, if not the first, event in the
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clonal evolution of hematological disorders (Jan et al.
2012; Itzykson et al. 2013). Therefore, it is tempting to
speculate that inactivating somatic TET2 mutations can
exist latently in hematopoietic cells for years if not de-
cades. During this period, enhancer methylation patterns
may progressively deteriorate and result in aberrant gene
expression and clonal dominance. Moreover, in some
individuals, these premalignant cells can acquire a coop-
erating mutation whose characteristics drive the de-
velopment of one of the wide range of hematological
malignancies associated with TET2 mutations. Thus,
careful examination of the epigenetic state of enhancer el-
ements in these patients can potentially unravel the first
molecular events that lead to initiation of the disease state
and potentially lead to the identification of druggable can-
didates for targeting the full clonal hierarchy of malignant
hematopoietic cells.
Materials and methods
Mice and in vitro cell culture systems
The conditional Tet2fl/fl mouse line described previously (Quiv-
oron et al. 2011) and derived Cre lines were housed according to
institutional guidelines. All animal work was performed under
the approval of the Danish Animal Ethical Committee. Primary
hematopoietic cell lines expressing MLL-AF9 in the Tet2fl/fl;
CreER background were generated andmaintained in suspension
medium as previously described (Somervaille and Cleary 2006).
Primary Tet2fl/fl;CreER HSPCs freshly transduced with MigR1-
AE-IRES-GFP or MigR1-AE9a-IRES-GFP (Yan et al. 2006) were
sorted for GFP and plated in methylcellulose medium (M3534,
StemCell Technologies). After three rounds of replating (each
lasting 5 d), the cells were shifted to grow in suspension in nontis-
sue culture-treated plasticware in medium containing 1× Stem-
Pro-34 SFM (Invitrogen), 1× L-glutamine, with SCF (CHO
producer cell line), 10 ng/mL IL-3 (Peprotech), 10 ng/mL IL-6
(Peprotech), and 0.1 mM 2-mercapto-ethanol. To induce the
CreER-mediated excision of Tet2, the cells were treated with
200 nM 4-OHT (experimental) or EtOH (control) for two passages
(4 d). The cells were subsequently washed to remove residual
4-OHT and passaged every 2 d for a total of 10–20 passages.
Gene expression analysis
Total RNA fromFACS-sorted in vivo L-GMP cells aswell aswild-
type GMP cells (Lin−cKit+Sca1−CD16/32+CD150−) were labeled
and hybridized to Agilent SurePrint G3 Mouse GE 8x60K arrays.
Total RNA from FACS-sorted iGMP cells (GFP+, Gr1−, Mac1−,
CD16/32+) from Tet2fl/fl;AE and Tet2−/−;AE cultures at passage
2 and passage 10 were hybridized to GeneChip Mouse Gene ST
2.0 arrays (Affymetrix).
ChIP-seq and 5hmC-DIP-seq
ChIP experiments (α-H3K4me1, α-H3K4me3, and α-H3K27ac)
were performed essentially as described previously (Williams
et al. 2011) on duplicate samples of Tet2fl/fl;AE and Tet2−/−;AE
cells at passage 10 after deletion. 5hmC-DIP-seq was performed
as described previously (Williams et al. 2011) on duplicate sam-
ples of Tet2fl/fl;AE and Tet2−/−;AE cells at passage 5 after Tet2
deletion (passage in which maximum global 5hmC depletion
was achieved).
eRRBS
eRRBS libraries were generated as described (Akalin et al. 2012).
In brief, ∼1 μg of genomic DNA was digested with MspI enzyme
overnight followed by phenol/chloroform extraction. After li-
brary generation using preannealed methylcytosine-containing
Illumina adaptors (TruSeq DNA sample preparation kit, Illu-
mina) and gel-based size selection, the ligated fragments were
treated with bisulfite (EZ DNA methylation kit, Zymo) to con-
vert unmethylated cytosines. Finally, the converted fragments
were PCR-amplified (15 PCR cycles) and sequenced on an Illu-
mina HiSeq2000 using 100-bp single-end sequencing.
Enhancers
Active distal enhancerswere defined as promoter-distal (nonover-
lapping with a region extending ±2.5 kb from all transcription
start sites), overlapping ChIP-seq-enriched regions of H3K27ac
and H3K4me1 histone modifications with low mean H3K4me3
enrichment in duplicate samples. The resulting regions separated
by <1 kb were merged to avoid redundant detection. This yielded
a final high-confidence map of enhancers comprising a total of
8739 in Tet2fl/fl;AE cells and 9595 in Tet2−/−;AE cells.
Analysis of methylation state in TET2-deficient AML patients
TCGA Illumina Infinium 450k methylation array data and pa-
tient mutational analysis data were downloaded from the
TCGA homepage (The Cancer Genome Atlas Research Network
2013). Each probe on the array was assigned to a category (gene
body, promoter, CpG islands, and enhancers). Human predicted
enhancers were defined as in Andersson et al. (2014). Probes
that did not fall into any of the above categories were defined as
intergenic.
Accession numbers
Raw and processed data sets are available for download at the
Gene Expression Omnibus (GEO) database under the accession
number GSE59591.
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